Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00921752
First received: June 12, 2009
Last updated: December 3, 2009
Last verified: December 2009

June 12, 2009
December 3, 2009
May 2009
Not Provided
  • Percent rate of patients achieving target LDL cholesterol goals [ Time Frame: On each of the 3 visits performed during the study ] [ Designated as safety issue: No ]
  • Percent rate of patients achieving 50% or more reduction in LDL-cholesterol [ Time Frame: On each of the 3 visits performed during the study ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00921752 on ClinicalTrials.gov Archive Site
  • Percent rate of patients achieving target secondary (total Ch, triglycerides, HDL Ch) goals [ Time Frame: On each of the 3 visits performed during the study ] [ Designated as safety issue: No ]
  • Percent rate of compliance among patients in the study [ Time Frame: On each of the 3 visits performed during the study ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)
C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)

To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Ambulatory clinics

Cardiovascular Risk
Not Provided
Patients at high cardiovascular risk

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1500
November 2009
Not Provided

Inclusion Criteria:

  • Patients at high cardiovascular risk according to Framingham or SCORE rates

Exclusion Criteria:

  • Not eligible for lipid or statin therapy
  • Intolerance to therapy
  • Patients at low or intermediate CV risk
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Hungary
 
NCT00921752
NIS-CHU-DUM-2009/1
No
MC MD, AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Mark Laszlo, MD, PHD County Hospital Bekes, Gyula
Study Director: Csaba Csongvai, MD AstraZeneca Hungary
Study Chair: Eva Gulyas AstraZeneca Hungary
AstraZeneca
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP